Kiniksa Pharmaceuticals Ltd (KNSA)
$17.985
+0.13
(+0.7%)▲
Live
Insights on Kiniksa Pharmaceuticals Ltd
Decreasing Revenue
Revenue is down for the last 2 quarters, 83.39M → 79.85M (in $), with an average decrease of 4.2% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, 25.23M → -17.70M (in $), with an average decrease of 170.2% per quarter
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 240.7% return, outperforming this stock by 232.0%
Performance
- $17.55$18.09$17.99
2.45%
Downside
Day's Volatility :2.99%
Upside
0.55%
- $10.65$22.09$17.99
40.8%
Downside
52 Weeks Volatility :51.79%
Upside
18.56%
Returns
| Period | Kiniksa Pharmaceuticals Ltd | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -2.67% | 1.7% | 0.0% |
6 Months | 17.73% | 11.3% | 0.0% |
1 Year | 61.34% | 5.4% | 1.3% |
3 Years | 5.68% | 13.9% | -22.1% |
Highlights
Market Capitalization | 1.2B |
Book Value | $6.23 |
Earnings Per Share (EPS) | 0.2 |
PE Ratio | 88.4 |
Wall Street Target Price | 28.75 |
Profit Margin | 5.21% |
Operating Margin TTM | 0.1% |
Return On Assets TTM | -3.19% |
Return On Equity TTM | 3.37% |
Revenue TTM | 270.3M |
Revenue Per Share TTM | 3.86 |
Quarterly Revenue Growth YOY | 34.8% |
Gross Profit TTM | 173.2M |
EBITDA | -22.9M |
Diluted Eps TTM | 0.2 |
Quarterly Earnings Growth YOY | 5.5 |
EPS Estimate Current Year | -0.16 |
EPS Estimate Next Year | 0.05 |
EPS Estimate Current Quarter | -0.14 |
EPS Estimate Next Quarter | -0.17 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 59.86%
Technicals Summary
Sell
Neutral
Buy
Kiniksa Pharmaceuticals Ltd is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Kiniksa Pharmaceuticals Ltd | -10.52% | 17.73% | 61.34% | 5.68% | 12.12% |
 Moderna, Inc. | -1.39% | 41.81% | -19.31% | -38.71% | 322.88% |
 Regeneron Pharmaceuticals, Inc. | -5.68% | 13.74% | 14.81% | 80.88% | 159.02% |
 Novo Nordisk A/s | -2.24% | 29.49% | 49.67% | 240.51% | 421.0% |
 Vertex Pharmaceuticals Incorporated | -3.67% | 10.39% | 20.74% | 84.71% | 129.52% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Kiniksa Pharmaceuticals Ltd | 88.4 | 88.4 | NA | -0.16 | 0.03 | -0.03 | NA | 6.23 |
Moderna, Inc. | 24.73 | NA | 0.0 | -6.77 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.13 | 26.13 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 48.36 | 48.36 | 2.4 | 3.34 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 29.17 | 29.17 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Kiniksa Pharmaceuticals Ltd | Buy | $1.2B | 12.12% | 88.4 | 5.21% |
Moderna, Inc. | Buy | $41.3B | 322.88% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.6B | 159.02% | 26.13 | 30.14% |
Novo Nordisk A/s | Buy | $573.9B | 421.0% | 48.36 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $104.7B | 129.52% | 29.17 | 36.68% |
Institutional Holdings
BlackRock Inc
4.50%Vanguard Group Inc
4.20%Rubric Capital Management LP
4.12%Fairmount Funds Management LLC
4.08%Baker Bros Advisors LP
3.98%Goldman Sachs Group Inc
2.58%
Company Information
kiniksa pharmaceuticals combines an experienced management team and significant committed capital in order to acquire, develop, and commercialize therapeutics treating devastating diseases with high unmet needs.
Organization | Kiniksa Pharmaceuticals Ltd |
Employees | 297 |
CEO | Mr. Sanj K. Patel |
Industry | Health Technology |
